We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Three Best Genomics Stocks for Your Portfolio in 2026
Read MoreHide Full Article
An updated edition of the Feb. 20, 2026, article.
Genomics involves a thorough study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). It involves understanding how genes function in a particular living being and how they interact with each other and their environment.
Given the recent promising breakthroughs in this field, the space is drawing interest from pharmaceutical and biotechnology companies.
It is important to distinguish between genetics and genomics. Genetics focuses on individual genes and their functions, whereas genomics aims to characterize the entire set of genes in an organism, examining how they interact with one another and the environmental factors to influence biological processes.
Insights from genomic research are increasingly being used to evaluate how patients respond to specific drugs. These findings are also driving the development of precise, more targeted treatments, contributing to the advancement of personalized medicine. As demand for innovative therapies continues to grow, genomics is poised to play an increasingly central role in the future of healthcare, despite the complexity inherent in genome-scale research.
The expanding genomics landscape has also supported the growth of synthetic biology, which applies engineering principles to biology. This emerging field involves redesigning organisms for diverse applications, including drug discovery, disease detection, enzyme engineering, gene editing and foundational research.
A key driver of progress in genomics has been the dramatic reduction in the cost, time and technical effort required to sequence an individual’s genome. A prominent player in this field is Illumina (ILMN - Free Report) , widely recognized for its leadership in sequencing and array-based technologies for genetic analysis.
While many companies are using genomic sequencing to create solutions across healthcare and other industries, diagnostic firms are leveraging sequencing data to identify genetic variations and link them to known medical conditions.
Another transformative advancement is the emergence of genome-editing technologies, most notably CRISPR/Cas9 systems. Companies specializing in gene editing, such as CRISPR Therapeutics AG (CRSP - Free Report) and Beam Therapeutics (BEAM - Free Report) , are exploring these tools to develop treatments (and potentially cures) for diseases caused by genetic mutations. By enabling precise modifications to DNA, genome editing offers the possibility of correcting harmful genetic defects at their source.
According to Fortune Business Insights, the global genomics market was valued at $34.23 billion in 2025 and is expected to expand from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% over the period.
Per a Grandview Research article, the global synthetic biology market size was valued at $18.94 billion in 2025 and is projected to reach $69.18 billion by 2033, at a CAGR of 17.7% from 2026 to 2033.
If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, investors may consider adding stocks like Pacific Biosciences of California (PACB - Free Report) , GeneDx Holdings Corp. (WGS - Free Report) and Caribou Biosciences, Inc. (CRBU - Free Report) to their portfolios.
Pacific Biosciences of California is a life science technology company that designs, develops and manufactures advanced sequencing solutions. The company is focused on creating some of the world’s most advanced sequencing systems to provide customers with the most complete and accurate study of genomes, transcriptomes and epigenomes.
PACB’s portfolio, led by its HiFi long-read sequencing technology, supports a wide range of applications spanning human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology and other emerging fields.
Pacific Biosciences’ customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies and agricultural companies. The company has collaborated with n-Lorem Foundation and EspeRare to advance precision therapies for rare genetic diseases.
GeneDx Holdings is a leading player in rare disease diagnostics, focused on advancing genomic insights to improve patient outcomes. The company leverages deep clinical expertise, proprietary technology and its expansive GeneDx Infinity dataset — one of the largest rare disease genomic repositories globally — to support accurate and timely diagnoses.
Its core testing offerings, ExomeDx and GenomeDx, are highly regarded among clinicians and have received FDA Breakthrough Device Designation, underscoring their clinical utility and innovation. Beyond diagnostics, GeneDx is also positioning its dataset as a valuable asset for biopharma, enabling AI-driven discovery and development.
With more than 25 years of experience, over 4,800 genetic diseases diagnosed, and a robust publication record, GeneDx is building a scalable genomics platform that could play a central role in the evolution of precision medicine.
WGS currently sports a Zacks Rank #1.
Caribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, is using its genome-editing platform, including its Cas12a chRDNA technology, for the development of engineered cell therapies with improved durability and anti-tumor activity.
Its proprietary genome-editing platform is built around Cas12a chRDNA technology to deliver enhanced precision. The company’s lead programs include vispacabtagene regedleucel (vispa-cel) and CB-011, both off-the-shelf CAR-T cell therapies intended to expand treatment access and provide rapid therapeutic intervention for patients with hematologic malignancies.
The FDA granted vispa-cel Regenerative Medicine Advanced Therapy (“RMAT”), Fast Track, and Orphan Drug designations for B-NHL. The regulatory body recently granted RMAT designation to CB-011 for the treatment of relapsed or refractory multiple myeloma (r/r MM). The successful development of any of these therapies will be a significant boost for CRBU.
CRBU currently carries a Zacks Rank #2 (Buy). Shares of this biotech company have gained 21.4% year to date.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Three Best Genomics Stocks for Your Portfolio in 2026
An updated edition of the Feb. 20, 2026, article.
Genomics involves a thorough study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). It involves understanding how genes function in a particular living being and how they interact with each other and their environment.
Given the recent promising breakthroughs in this field, the space is drawing interest from pharmaceutical and biotechnology companies.
It is important to distinguish between genetics and genomics. Genetics focuses on individual genes and their functions, whereas genomics aims to characterize the entire set of genes in an organism, examining how they interact with one another and the environmental factors to influence biological processes.
Insights from genomic research are increasingly being used to evaluate how patients respond to specific drugs. These findings are also driving the development of precise, more targeted treatments, contributing to the advancement of personalized medicine. As demand for innovative therapies continues to grow, genomics is poised to play an increasingly central role in the future of healthcare, despite the complexity inherent in genome-scale research.
The expanding genomics landscape has also supported the growth of synthetic biology, which applies engineering principles to biology. This emerging field involves redesigning organisms for diverse applications, including drug discovery, disease detection, enzyme engineering, gene editing and foundational research.
A key driver of progress in genomics has been the dramatic reduction in the cost, time and technical effort required to sequence an individual’s genome. A prominent player in this field is Illumina (ILMN - Free Report) , widely recognized for its leadership in sequencing and array-based technologies for genetic analysis.
While many companies are using genomic sequencing to create solutions across healthcare and other industries, diagnostic firms are leveraging sequencing data to identify genetic variations and link them to known medical conditions.
Another transformative advancement is the emergence of genome-editing technologies, most notably CRISPR/Cas9 systems. Companies specializing in gene editing, such as CRISPR Therapeutics AG (CRSP - Free Report) and Beam Therapeutics (BEAM - Free Report) , are exploring these tools to develop treatments (and potentially cures) for diseases caused by genetic mutations. By enabling precise modifications to DNA, genome editing offers the possibility of correcting harmful genetic defects at their source.
According to Fortune Business Insights, the global genomics market was valued at $34.23 billion in 2025 and is expected to expand from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% over the period.
Per a Grandview Research article, the global synthetic biology market size was valued at $18.94 billion in 2025 and is projected to reach $69.18 billion by 2033, at a CAGR of 17.7% from 2026 to 2033.
If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, investors may consider adding stocks like Pacific Biosciences of California (PACB - Free Report) , GeneDx Holdings Corp. (WGS - Free Report) and Caribou Biosciences, Inc. (CRBU - Free Report) to their portfolios.
Explore 37 cutting-edge investment themes with Zacks Thematic Investing Screens and uncover your next big opportunity.
3 Genomics Stocks to Consider
Pacific Biosciences of California is a life science technology company that designs, develops and manufactures advanced sequencing solutions. The company is focused on creating some of the world’s most advanced sequencing systems to provide customers with the most complete and accurate study of genomes, transcriptomes and epigenomes.
PACB’s portfolio, led by its HiFi long-read sequencing technology, supports a wide range of applications spanning human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology and other emerging fields.
Pacific Biosciences’ customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies and agricultural companies. The company has collaborated with n-Lorem Foundation and EspeRare to advance precision therapies for rare genetic diseases.
PACB’s shares have risen 1.6% over the past year. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
GeneDx Holdings is a leading player in rare disease diagnostics, focused on advancing genomic insights to improve patient outcomes. The company leverages deep clinical expertise, proprietary technology and its expansive GeneDx Infinity dataset — one of the largest rare disease genomic repositories globally — to support accurate and timely diagnoses.
Its core testing offerings, ExomeDx and GenomeDx, are highly regarded among clinicians and have received FDA Breakthrough Device Designation, underscoring their clinical utility and innovation. Beyond diagnostics, GeneDx is also positioning its dataset as a valuable asset for biopharma, enabling AI-driven discovery and development.
With more than 25 years of experience, over 4,800 genetic diseases diagnosed, and a robust publication record, GeneDx is building a scalable genomics platform that could play a central role in the evolution of precision medicine.
WGS currently sports a Zacks Rank #1.
Caribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, is using its genome-editing platform, including its Cas12a chRDNA technology, for the development of engineered cell therapies with improved durability and anti-tumor activity.
Its proprietary genome-editing platform is built around Cas12a chRDNA technology to deliver enhanced precision. The company’s lead programs include vispacabtagene regedleucel (vispa-cel) and CB-011, both off-the-shelf CAR-T cell therapies intended to expand treatment access and provide rapid therapeutic intervention for patients with hematologic malignancies.
The FDA granted vispa-cel Regenerative Medicine Advanced Therapy (“RMAT”), Fast Track, and Orphan Drug designations for B-NHL. The regulatory body recently granted RMAT designation to CB-011 for the treatment of relapsed or refractory multiple myeloma (r/r MM).
The successful development of any of these therapies will be a significant boost for CRBU.
CRBU currently carries a Zacks Rank #2 (Buy). Shares of this biotech company have gained 21.4% year to date.